Good News for Humankind

Your daily spark of possibility

The world is changing — for the better, and in real, indisputable ways. Climate breakthroughs. Justice wins. Scientific discoveries. From people you’ve never heard of. In places you wouldn’t expect.

Every weekday, I send a piece of good news from around the world — not to sugarcoat reality, but to remind you that change is possible.

Every weekday morning at 7am. Or sign up for the weekly digest.

What Readers Are Saying

It restores my faith that homo sapiens sapiens, even if not in everything and always, deserves the name it has given itself.

Eszter

Peter is all passion. He’s spent years working toward the greater good by helping his readership and community becoming the best version of themselves. His thoughtfully curated positive news stories stem from his genuine and effortless capacity to empathize. You’re an inspiration, Peter. Thank you!

Athos Cakiades Company Name

Good News daily restores my faith in humanity and in Universal Source; I’ve shared this newsletter with family and friends and we love it! Hurray for Peter’s inspiration and generosity! So grateful.

Eve Thompson Company Name

I forward this to friends who need a remedy for despair.

Alice PrestonCompany Name

Good News for Humankind has been a crack of light in my inbox for years
because it provides a some counter balance to the dystopian info-tsunami
that passes for news from other sources.

Tim TaylorCompany Name

The Latest Good News

Search

Topic

Country

Actor

Child getting hearing test, for article on gene therapy for deafness

2026 C.E. May 22

U.S. FDA approves first gene therapy for inherited deafness, offered free to U.S. patients

Gene therapy can now restore hearing to children born deaf — and Regeneron is giving it away free to U.S. families. In a trial of 20 children with rare OTOF mutations, 16 gained meaningful hearing within about five months, and several were brought to essentially normal hearing. One toddler covered his ears when an ambulance siren passed — his first sign of sound. Instead of charging up to $4 million per child, as is...

Seabird, for article on PFAS levels in Canadian seabird eggs

2026 C.E. May 22

Banned ‘forever chemicals’ fell up to 74% in Canadian seabird eggs over 55 years

Toxic "forever chemical" levels in northern gannet eggs from Canada's largest seabird colony have dropped 74% from their peak, according to a new peer-reviewed study tracking 55 years of data. Researchers on Bonaventure Island watched PFOS concentrations climb through the late 1990s, cross the threshold considered dangerous to the birds themselves, and then steadily fall as governments and manufacturers began phasing the chemicals out. Because gannets sit near the top of the marine food...

Mother and baby, for article on Chile maternity leave reform

2026 C.E. May 22

Chile’s maternity leave reform lifted mothers’ employment without wage penalties

Chile's maternity leave reform delivered something policymakers rarely get to claim: a sustained employment boost for mothers, with no wage penalty in sight. After the country doubled postnatal leave from 12 to 24 weeks in 2011, eligible mothers were 6.8 percentage points more likely to hold formal jobs in the three years after returning to work, according to a study in the Journal of Development Economics. The biggest gains went to women with shorter work...

Pangolin, for article on Chinese pangolin population

2026 C.E. May 20

Chinese pangolins rebound in southern China for the first time this century

Chinese tree pangolins are quietly returning to Guangdong Province, where wildlife monitors now count 1,778 of the scaly, ant-eating mammals in the wild — places where local populations had crashed to zero just years ago. Six years after China granted the species its highest protection status, a network of 690 infrared cameras is tracking the rebound in near-real time, while the country's first dedicated pangolin research and breeding center has opened in Guangzhou. China...

Cancer patient reading a book, for article on pre-surgery immunotherapy

2026 C.E. May 20

Bowel cancer patients see zero relapses three years after new immunotherapy

Bowel cancer patients in a small U.K. trial saw zero relapses nearly three years after receiving immunotherapy before surgery — a striking result for all 32 participants, even those who still had traces of cancer after treatment. By comparison, the standard path of surgery followed by chemotherapy sees roughly one in four patients relapse within three years. The trial focused on people with a specific genetic profile that makes tumors more visible to the...

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153

Enjoying these stories? Get one delivered to your inbox every weekday morning — free.

Go to good news archives for specific countries, institutions, topics, etc.